The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Open accessAbstract
Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non–small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citation(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Self-citationDouillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry
Piccirillo, J. F. (2004) · JAMA · doi:10.1001/jama.291.20.2441 · Cited by 1,205
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4855 · Cited by 974
Self-citationScagliotti, G. V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg059 · Cited by 593
Arriagada, R., Dunant, A., Pignon, J.-P., Bergman, B., Chabowski, M., Grunenwald, D., Kozlowski, M., Le Péchoux, C., Pirker, R., Pinel, M.-I. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2272 · Cited by 394
Second Lung Cancers in Patients After Treatment for an Initial Lung Cancer
Johnson, B. E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1335 · Cited by 393
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., & Green, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7019 · Cited by 380
Self-citationImpact of comorbidity on lung cancer survival
Tammemagi, C. M., Neslund‐Dudas, C., Simoff, M., & Kvale, P. (2003) · International Journal of Cancer · doi:10.1002/ijc.10882 · Cited by 282
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2008) · The Lancet · doi:10.1016/s0140-6736(08)60069-0 · Cited by 279
Smoking and Lung Cancer Survival
Tammemagi, C. M., Neslund-Dudas, C., Simoff, M., & Kvale, P. (2004) · Chest · doi:10.1378/chest.125.1.27 · Cited by 268
Second Primary Cancers Related to Smoking and Treatment of Small-Cell Lung Cancer
Tucker, M. A., Murray, N., Shaw, E. G., Ettinger, D. S., Mabry, M., Huber, M. H., Feld, R., Shepherd, F. A., Johnson, D. H., Grant, S. C., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1782 · Cited by 217
Self-citationComorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer
Firat, S., Bousamra, M., Gore, E., & Byhardt, R. W. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02741-9 · Cited by 199
Noncancer Causes of Death in Survivors of Testicular Cancer
Fossa, S. D., Gilbert, E., Dores, G. M., Chen, J., McGlynn, K. A., Schonfeld, S., Storm, H., Hall, P., Holowaty, E., Andersen, A., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk111 · Cited by 197
Schiller, J. H., Adak, S., Feins, R. H., Keller, S. M., Fry, W. A., Livingston, R. B., Hammond, M. E. M., Wolf, B., Sabatini, L., Jett, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.448 · Cited by 192
Self-citationStrauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. A., Vokes, E. E., & Green, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7007 · Cited by 178
Self-citationPrognostic value of smoking status in operated non-small cell lung cancer
Sardari Nia, P., Weyler, J., Colpaert, C., Vermeulen, P., Marck, E. V., & Schil, P. V. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.08.011 · Cited by 176
Adjuvant chemotherapy in stage IB nonsmall cell lung cancer
Wauters, I., & Vansteenkiste, J. (2009) · Breathe · doi:10.1183/18106838.0504.361 · Cited by 11
Cited by
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Treatment of Stage I and II Non-small Cell Lung Cancer
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013) · Chest · doi:10.1378/chest.12-2359 · Cited by 1,440
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
O’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 774
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Metadata
- Authors
- Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., Johnson, D. H., Kesler, K. A., Green, M., Vincent, M., Cormier, Y., Goss, G., Findlay, B., Johnston, M., Tsao, M.-S., & Shepherd, F. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-01
- Volume
- 28
- Issue
- 1
- Pages
- 29-34
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1989169445
- Cited by
- 425
- References
- 22
- FWCI
- 20.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.